• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nektar Therapeutics

    3/14/25 4:22:46 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTR alert in real time by email
    S-8 1 d864612ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 14, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    NEKTAR THERAPEUTICS

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   94-3134940

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification Number)

    455 Mission Bay Boulevard South

    San Francisco, California 94158

    (Address of Principal Executive Offices and Zip Code)

    Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan

    (Full Title of the Plan)

    Mark A. Wilson

    Chief Legal Officer

    Nektar Therapeutics

    455 Mission Bay Boulevard South

    San Francisco, California 94158

    415-482-5300

    (Name, Address, and Telephone Number, Including Area Code, of Agent for Service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    On March 27, 2024, the board of directors of the Registrant approved an amendment to Registrant’s Amended and Restated 2017 Performance Incentive Plan (as amended, the “PIP”), pursuant to which the number of shares of common stock, par value $0.0001 per share (the “Common Stock”), reserved and available for issuance under the PIP increased by 8,000,000 shares subject to stockholder approval, which was received on June 5, 2024. This Registration Statement on Form S-8 registers these 8,000,000 additional shares of Common Stock. The additional shares available for issuance under the PIP are of the same class as other securities relating to the PIP for which the Registrant’s registration statements filed on Form S-8 (Registration No. 333-218777) on June 15, 2017, on Form S-8 (Registration No. 333-226004) on June 29, 2018, on Form S-8 (Registration No. 333-242327) on August 7, 2020, on Form S-8 (Registration No. 333-258900) on August 18, 2021, on Form S-8 (Registration No. 333-266580) on August 5, 2022 and on Form S-8 (Registration No. 333-273962) on August 14, 2023 are effective.

    The information contained in the Registrant’s prior registration statements on Form S-8 is hereby incorporated by reference pursuant to General Instruction E, except for “Item 8. Exhibits.”


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.

    Exhibits.

     

    Exhibit
    No.
      

    Description

      4.1*    Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 1998).
      4.2*    Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc. (incorporated by reference to Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2000).
      4.3*    Certificate of Ownership and Merger of Nektar Therapeutics (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on January 23, 2003).
      4.4*    Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics (incorporated by reference to Exhibit 3.6 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2009).
      4.5*    Amended and Restated Bylaws of Nektar Therapeutics (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on December 16, 2022).
      4.6*    Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed on August 9, 2024).
      4.7*    Specimen Stock Certificate Evidencing the Shares of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on January 23, 2003).
      4.8*    Description of Securities Registered Pursuant to Section  12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020).
      5.1**    Opinion of Goodwin Procter LLP with respect to the validity of the securities.
     23.1**    Consent of Independent Registered Public Accounting Firm.
     23.2**    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
     24.1**    Power of Attorney (set forth on the signature page of this Registration Statement).
      107**    Filing Fee Table

     

    *

    Previously filed with the Commission and incorporated herein by reference.

    **

    Filed herewith

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on March 14, 2025.

     

    NEKTAR THERAPEUTICS
    By:   /s/ Howard W. Robin
      Howard W. Robin
      Chief Executive Officer and President

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Howard W. Robin and Mark A. Wilson, and each of them, acting individually and without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto, and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and to perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them individually, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Howard W. Robin

    Howard W. Robin

      

    Chief Executive Officer, President, and Director

    (Principal Executive Officer)

      March 14, 2025

    /s/ Sandra Gardiner

    Sandra Gardiner

      

    Interim Chief Financial Officer

    (Principal Financial and Accounting Officer)

      March 14, 2025

    /s/ Robert B. Chess

    Robert B. Chess

       Director, Chairman of the Board of Directors   March 14, 2025

    /s/ Jeffrey R. Ajer

    Jeffrey R. Ajer

       Director   March 14, 2025

    /s/ R. Scott Greer

    R. Scott Greer

       Director   March 14, 2025

    /s/ Roy A. Whitfield

    Roy A. Whitfield

       Director   March 14, 2025

    /s/ Diana M. Brainard

    Diana M. Brainard

       Director   March 14, 2025

     

    2

    Get the next $NKTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NKTR

    DatePrice TargetRatingAnalyst
    4/11/2025$2.00Hold → Buy
    Jefferies
    3/14/2025$6.00Perform → Outperform
    Oppenheimer
    1/8/2025$4.00Buy
    B. Riley Securities
    12/10/2024$6.50Buy
    H.C. Wainwright
    11/4/2024$7.00Overweight
    Piper Sandler
    9/30/2024$4.00Buy
    BTIG Research
    6/28/2024$2.00Buy
    Rodman & Renshaw
    11/20/2023Underweight
    JP Morgan
    More analyst ratings

    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nektar Therapeutics Reports First Quarter 2025 Financial Results

      SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a

      5/8/25 4:15:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

      SAN FRANCISCO, May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web

      5/1/25 6:00:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

      SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-pres

      3/20/25 6:00:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTR
    Financials

    Live finance-specific insights

    See more
    • Nektar Therapeutics Reports First Quarter 2025 Financial Results

      SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a

      5/8/25 4:15:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

      SAN FRANCISCO, May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web

      5/1/25 6:00:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 20

      3/12/25 4:15:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nektar Therapeutics

      SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

      11/14/24 12:17:04 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nektar Therapeutics

      SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)

      11/14/24 9:18:10 AM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nektar Therapeutics

      SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

      3/15/24 4:18:49 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NKTR
    SEC Filings

    See more
    • Nektar Therapeutics upgraded by Jefferies with a new price target

      Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00

      4/11/25 8:15:16 AM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Nektar Therapeutics from Perform to Outperform and set a new price target of $6.00

      3/14/25 7:38:49 AM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Nektar Therapeutics with a new price target

      B. Riley Securities initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00

      1/8/25 8:04:14 AM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief R&D Officer Zalevsky Jonathan sold $10,403 worth of shares (10,300 units at $1.01), decreasing direct ownership by 3% to 316,604 units (SEC Form 4)

      4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

      2/21/25 6:07:52 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Wilson Mark Andrew sold $11,150 worth of shares (11,040 units at $1.01), decreasing direct ownership by 3% to 324,292 units (SEC Form 4)

      4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

      2/21/25 6:06:43 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Robin Howard W sold $24,012 worth of shares (23,774 units at $1.01), decreasing direct ownership by 2% to 1,086,901 units (SEC Form 4)

      4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

      2/21/25 6:04:25 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

      5/8/25 4:20:26 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nektar Therapeutics

      DEF 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)

      4/25/25 4:15:48 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Nektar Therapeutics

      PRE 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)

      4/15/25 4:39:35 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTR
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

      Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

      1/22/24 8:23:00 AM ET
      $DMAC
      $MRNS
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors

      BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and

      5/11/22 8:01:00 AM ET
      $NKTR
      $TWST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.

      SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple

      11/15/21 8:30:00 AM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care